By Lars Mucklejohn GSK, formerly known as Glaxosmithkline, has agreed to acquire biopharmaceutical company Aiolos Bio in a deal worth at least £785m, as it hails access to the latter company’s twice-yearly asthma treatment. The deal, subject to regulatory approval, includes a $1bn upfront payment and up to $400m in “success-based regulatory milestone payments,” GSK said on Tuesday morning. Aolos, founded just last year, is a UK-based clinical-stage firm focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions. The takeover means GSK will …